# Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

> **NCT00128102** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 661 (actual)

## Conditions studied

- Mesothelioma
- Lung Cancer

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00128102
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-30
- **Primary completion:** 2011-07-15
- **Final completion:** 2011-11-21
- **Target enrollment:** 661 (ACTUAL)
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128102, "Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00128102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*